UBC Acquires Evidinno Outcomes Research to Strengthen Real-World Evidence and Health Economics Capabilities
核心洞察
United BioSource LLC has acquired Evidinno Outcomes Research Inc. (搜索), a Vancouver-based healthcare research consulting firm specializing in real-world evidence, epidemiology, and health economic analysis.
The acquisition enhances UBC's ability to deliver regulatory-grade evidence synthesis, comparative effectiveness research, and health technology assessment solutions across the drug development lifecycle.
Evidinno (搜索) will operate as a wholly owned subsidiary, combining its AI-enabled analytical capabilities with UBC's global platform to support biopharma clients in demonstrating treatment value for regulatory and reimbursement decisions.
United BioSource LLC (UBC) has acquired Evidinno Outcomes Research Inc. (搜索), a strategic move that significantly expands the company's capabilities in real-world evidence generation and health economics and outcomes research (HEOR). The acquisition positions UBC to better serve biopharma clients navigating the increasingly complex landscape of drug approval, reimbursement, and market access.
Strategic Expansion in Evidence Generation
Evidinno (搜索), headquartered in Vancouver, Canada, brings specialized expertise in real-world evidence, epidemiology, evidence synthesis, and advanced statistical and economic analysis. The company's team of seasoned epidemiologists, health economists, and research scientists delivers market-leading health technology assessment (HTA) and regulatory-grade evidence synthesis solutions.
"Evidinno (搜索)'s scientific rigor and technology-enabled workflows deepen our ability to curate fit-for-purpose evidence and health economic and outcomes insights for our clients," said Aaron Berger, SVP Evidence Development Solutions at UBC. "Together, we will transform the evidence value chain and help sponsors answer important questions on the safety and effectiveness of treatments for patients."
Comprehensive Service Portfolio
The acquisition brings together complementary capabilities that span the entire drug development and commercialization continuum. Evidinno (搜索)'s offerings include AI-enabled, expert-led literature reviews, comparative effectiveness research, network meta-analyses, health economic modeling, HTA dossier development, and research consulting across the product lifecycle.
UBC's existing platform focuses on modernizing evidence development and patient access pathways through data acquisition technology embedded into study designs and execution for safety and value demonstration optimization. The combined entity will offer an integrated suite of consulting and evidence generation services spanning clinical development, regulatory strategy, and post-approval commercialization.
Market Access and Value Demonstration Focus
The acquisition comes at a time when healthcare systems worldwide are increasingly moving toward value-based reimbursement models, where demonstrating real-world benefit is as critical as showing clinical efficacy. Evidinno (搜索)'s expertise in producing regulatory-grade and health technology assessment evidence addresses the growing demand from payers and regulators who rely on such data to evaluate a therapy's true value.
"Joining UBC marks an important step in expanding the reach and influence of Evidinno (搜索)'s scientific and methodological expertise," said Dr. Mir Sohail Fazeli, MD, PhD, Chief Executive Officer of Evidinno. "By combining our HTA- and regulatory-grade evidence synthesis solutions, real-world research, and economic modeling capabilities with UBC's global platform, we are well positioned to deliver robust, decision-ready evidence that supports sponsors and improves outcomes for patients world-wide."
Operational Integration
Evidinno (搜索) will operate as a wholly owned subsidiary of UBC, maintaining its specialized focus while benefiting from integration with UBC's global platform and resources. This structure allows for the preservation of Evidinno's scientific expertise while enabling broader reach and enhanced service delivery capabilities.
The acquisition reflects UBC's strategic focus on controlling the evidence pipeline as drug pricing and access face growing scrutiny from healthcare systems and regulators. Fairmount Partners (搜索) served as exclusive financial advisor to Evidinno (搜索) in the transaction, though financial terms were not disclosed.